HIF1A and neoplasm: Meanwhile, topotecan, a FDA-approved topoisomerase I inhibitor, has been shown to inhibit HIF-1α protein accumulation through a DNA damage-independent mechanism and thus delay both angiogenesis and tumor growth (140).